A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression

BACKGROUNDS: Pseudoprogression disease (PsPD) is commonly observed during glioblastoma (GBM) follow-up after adjuvant therapy. Because it is difficult to differentiate PsPD from true early progression of GBM, we have used a quantitative proteomics strategy to identify molecular signatures and develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peng, Guo, Zhengguang, Zhang, Yang, Gao, Zhixian, Ji, Nan, Wang, Danqi, Zou, Lili, Sun, Wei, Zhang, Liwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393599/
https://www.ncbi.nlm.nih.gov/pubmed/25866482
http://dx.doi.org/10.1186/s12953-015-0066-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393599/
https://www.ncbi.nlm.nih.gov/pubmed/25866482
http://dx.doi.org/10.1186/s12953-015-0066-5

Ejemplares similares